# V1 Empirics Check — openai/gpt-5.1-codex-mini (Variant A)

**Model:** openai/gpt-5.1-codex-mini
**Variant:** A
**Date:** 2026-04-03T20:18:30.891580

---

**Idea Fidelity**

The manuscript faithfully tracks the original idea manifest. It leverages the Mallinckrodt product-line expansion as a plausibly exogenous source of high-dose oxycodone introduction, operationalizes the shift-share instrument via pre-period Mallinckrodt distribution exposure, and uses ARCOS transactions to document county-level potency outcomes. The focus remains on potency composition rather than overdose outcomes, consistent with the stated research question, and the key policy relevance (generic competition on potency) is highlighted throughout. No major elements from the original concept appear to be omitted.

---

**Summary**

This paper documents how Mallinckrodt’s 2008 expansion into high-dose oxycodone created a “potency arms race” in the generic market, using 178 million ARCOS transactions to show that counties with higher pre-period Mallinckrodt exposure received disproportionately more potent pills after the launch. The identification relies on a shift-share-like instrument exploiting pre-existing distributor-manufacturer relationships and the timing of the product-line expansion, with a strong first stage, placebo tests, and event-study evidence supporting the interpretation that potency shifts are driven by supply-side portfolio decisions. The contribution is to emphasize that generic competition operated on the potency margin, shaping the geography of opioid strength in ways invisible to aggregate volume statistics.

---

**Essential Points**

1. **Instrument Exogeneity Beyond Pre-Trends**: The validity of the shift-share instrument rests on the claim that pre-period Mallinckrodt share reflects logistics ties rather than latent county demand for potency. However, the balance test shows a strong negative correlation with pre-period potency, implying that high-share counties were systematically different. While the event study shows a pre-trend in the opposite direction, more evidence is needed that the instrument is not capturing other county-level trends in prescribing behavior (e.g., physician networks, insurer coverage, or socioeconomic factors) that correlate with being served by Mallinckrodt’s distributors. Consider providing additional covariate balance checks or exploiting instrument variation orthogonal to observable determinants of potency to bolster exogeneity.

2. **Interpretation of the First Stage as an IV Strategy**: The manuscript frames its exercise as a first stage (the shift-share predicts potency), but it never proceeds to a second-stage causal estimate linking potency changes to downstream outcomes. As written, the empirical strategy identifies the effect of Mallinckrodt exposure on potency, not the causal effect of potency on public health, making the policy interpretation about overdose risk somewhat speculative. The paper should clarify in the introduction and conclusion that it strictly estimates the supply-side potency mechanism and not the welfare impact unless a second stage is added with a credible instrumented link to outcomes (e.g., overdose deaths) or compelling external elasticity is used.

3. **Role of Other Manufacturers and Market Dynamics Post-2008**: The paper argues that Mallinckrodt’s high-dose launch drove potency increases, but generic entry and competition were broader phenomena—other firms also introduced high-dose formulations and distribution networks may have adjusted over time. Without explicitly modeling these dynamics, it is unclear whether the observed potency changes are attributable solely to Mallinckrodt’s expansion or to the broader market response triggered by it. Providing evidence that Mallinckrodt remained the dominant source of new high-dose pills (e.g., market share of 20–30mg formulations by manufacturer) or showing that counties with similar Mallinckrodt exposure but differing exposure to other firms’ launches behaved differently would strengthen the causal narrative.

If these essential issues cannot be addressed satisfactorily, the paper would be difficult to defend. At least two (instrument validity, scope of inference) require substantial justification beyond existing robustness checks.

---

**Suggestions**

1. **Strengthen Instrumental Narrative with Additional Descriptives**  
   - Map or tabulate the geographic distribution of 2006 Mallinckrodt share alongside baseline potency, overdose rates, and distributor networks to visually demonstrate that the variation is logistical rather than demand-driven.  
   - Include descriptive statistics on the distributor relationships—e.g., stability over time, concentration, and the proportion of counties served by the same distributor pairs—so readers understand the persistence of the supply-chain geography underpinning the shift-share.

2. **Augment the Event Study and Placebo Analyses**  
   - Although the event study suggests no positive pre-trends, include confidence bands or permutation tests (e.g., placebo expansions at other years) to show that observed post-2008 increases are not typical of other years.  
   - Expand the placebo exercise beyond hydrocodone to other opioids or even non-opioid Schedule II drugs served by the same distributors, which would provide stronger evidence that the instrument isolates oxycodone-specific potency shifts.

3. **Clarify the Economic Mechanism and Scope**  
   - Discuss in more detail why the product expansion should affect potency rather than quantities. For example, offer evidence on price stability (to rule out price competition) or on physician prescribing behavior (are doctors willing to write prescriptions for higher doses?).  
   - Consider adding a conceptual framework (even a brief one) that links the product-line decision, distribution exposure, and county potency outcomes, making explicit the assumptions needed for causal interpretation.

4. **Consider Additional Controls or Specifications to Capture Confounders**  
   - While the estimation is cross-sectional, conditioning on time-invariant county characteristics may help. Include baseline demographic or health-care supply controls (physician density, insurance coverage, socioeconomic status) interacted with time to account for differential trends.  
   - Alternatively, instrument in a panel setting (with county fixed effects) using year-by-year exposure to Mallinckrodt shipments, if feasible, to exploit within-county changes in the instrument rather than purely cross-sectional differences.

5. **Elaborate on the Policy Interpretation**  
   - The conclusion emphasizes implications for FDA oversight and antitrust policy. Expanding this discussion with citations to regulatory processes (e.g., how generic dose approval occurs) and explaining how regulators might monitor potency composition would ground the policy relevance.  
   - If possible, provide back-of-the-envelope calculations translating the estimated effect into additional morphine-equivalent milligrams per capita or potential overdose risk (citing existing literature linking potency to harms), carefully noting the limitations.

6. **Transparency About Data and Replication**  
   - Given the innovative use of ARCOS data, include in the appendix the precise definitions used to identify Mallinckrodt shipments, aggregation steps, and any data cleaning choices (e.g., handling of missing county identifiers). A table listing the NDCs or strengths counted as high-dose would also improve reproducibility.  
   - If feasible, provide a subset of anonymized summary tables or code snippets to allow replication of key steps without violating data sharing constraints.

By addressing these suggestions, the paper would more convincingly demonstrate that an industrial-organization event—Mallinckrodt’s product expansion—causally altered opioid potency geography, enhancing both its empirical credibility and its policy relevance.
